secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-015736
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B
----------------------------------------------------------------

- Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).
- BEAM-201 IND placed on clinical hold by FDA July 29; awaiting official letter.
- Patient enrollment in BEACON Phase 1/2 for BEAM-101 on track for 2H 2022.
- John Lo, Ph.D., appointed Chief Commercial Officer; Amended Verve deal adds CV target.
- Cash, cash equivalents and marketable securities $1.2B as of June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/0000950170-22-015736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/beam-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer